Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation Page 4 • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth • 17 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Steve Newlin Appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2013 2014 and beyond -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $38.38 March 7th, 2014 • 17 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 5 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% United States 66% Europe 14% Canada 7% Asia 6% Latin America 7% PP&S Specialty 53% Distribution 27% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target Ad ju st ed E ar ni ng s P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 6 PolyOne At A Glance Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty Specialty OI $5M $46M $87M $195M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 2013 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.2% 12 – 16% Global Specialty Engineered Materials 1.1% 9.3% 12 – 16% Designed Structures & Solutions -- 5.6% 8 – 10% Performance Products & Solutions 5.4% 7.2% 9 – 12% Distribution 2.6% 5.9% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.1% 15% 4) Adjusted EPS Growth N/A 31% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 Bridge To $2.50 Adjusted EPS By 2015 2015 EPS: $2.50 2013 EPS: $1.31 Mid single digit revenue CAGR Page 9 Mergers & Acquisitions Spartech accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 10 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 11 Unique and Innovative Solutions that Help Customers Win https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG Net Debt / EBITDA* = 1.8x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Significant Debt Maturities As of December 31, 2013 ($ millions) Page 12 Coupon Rates: 7.500% 7.375% 5.250% Debt Maturities & Pension Funding – 12/31/13 *TTM 12/31/2013 ** includes US-qualified plans only 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2013 Pension Funding** As of December 31, 2013 Free Cash Flow and Strong Balance Sheet Fund Investment •Targets that expand our: • Specialty offerings •End market presence •Geographic footprint •Operating Margin • Synergy opportunities •Adjacent material solutions •Expanding our sales, marketing, and technical capabilities • Investing in operational and LSS initiatives (including synergy capture) •Manufacturing alignment Organic Growth Share Repurchases Dividends Acquisitions Page 13 $0.16 $0.20 $0.24 $0.32 $0.00 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend • Repurchased ~5 million shares in 2013 • 15 million shares are available for repurchase under the current authorization The New PolyOne: A Specialty Growth Company 2015 Target: $2.50 Adjusted EPS Why Invest In PolyOne? Reconciliation to Condensed Consolidated Balance Sheets 2013 Short-term debt and current portion of long-term debt $ 12.7 Long-term debt 976.2 Less cash and cash equivalents (365.2) Net debt $ 623.7 Adjusted EBITDA 2013 Income before income taxes $ 151.0 Interest expense, net 63.5 Depreciation and amortization 108.8 Special items in EBITDA 31.7 Adjusted EBITDA $ 355.0 2 Platform sales and operating income (OI) 2006Y* 2013Y Global Specialty Engineered Materials sales $ 345.3 $ 615.5 Global Color, Additives and Inks sales 531.8 852.3 Designed Structures and Solutions sales - 597.4 Specialty Platform sales 877.1 2,065.2 Performance Products and Solutions sales 1,166.2 773.2 PolyOne Distribution sales 732.8 1,075.2 Corporate and eliminations (153.7) (142.4) Total sales $ 2,622.4 $ 3,771.2 Global Specialty Engineered Materials OI $ 3.9 $ 57.2 Global Color, Additives and Inks OI 8.9 104.0 Designed Structures & Solutions OI - 33.4 Specialty Platform OI 12.8 194.6 Performance Products and Solutions OI 64.2 56.0 PolyOne Distribution OI 19.2 63.3 Sunbelt Joint Venture OI 102.9 - Corporate and eliminations (4.6) (52.4) Special items in OI 39.1 (30.0) Operating income GAAP 233.6 231.5 Sunbelt equity income (107.0) - Special items in OI (39.1) 30.0 Adjusted operating income $ 87.5 $ 261.5 Global Specialty Engineered Materials - OI % of sales 1.1% 9.3% Global Color, Additives and Inks - OI % of sales 1.7% 12.2% Designed Structures & Solutions - OI % of sales - 5.6% Specialty platform OI - % of sales 1.5% 9.4% PP&S operating OI - % of sales 5.5% 7.2% Distribution OI - % of sales 2.6% 5.9% PolyOne OI adjusted - % of sales 3.3% 6.9% * Historical results include the Resin and Specialty Coatings businesses within the Performance Products and Solutions segment.

Microsoft PowerPoint - AVNT Q4 2023 Earnings Presentation v7 AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 3 R E S U L T S A N D 2 0 2 4 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A RY 1 4 , 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 O P E N I N G R E M A R K S DR. ASHISH KHANDPUR PRESIDENT & CEO 4 5 PORTFOLIO TRANSFORMATION 5 46% 66% 87% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2020 2023 % o f A dj us te d EB IT D A Commodity JVs Distribution Performance Products & Solutions Specialty Businesses Adjusted EBITDA from Specialty Applications SUSTAINABILITY AS A GROWTH DRIVER 7 LONG-TERM REVENUE GROWTH DRIVERS Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other 60%+ Key Growth Drivers Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other 0–2% Avient 6% END MARKET OBSERVATIONS (% OF COMPANY SALES) ENERGY DEFENSE TELECOMMUNICATIONS HEALTHCARE 8 TRANSPORTATION INDUSTRIAL BUILDING & CONSTRUCTION 9% CONSUMER 19% PACKAGING 23% 9 REGIONAL OBSERVATIONS (% OF COMPANY SALES) 9 41% 36% Q 4 2 0 2 3 R E S U LT S Q4 2023 PERFORMANCE VS.

Microsoft PowerPoint - AVNT M8 Investor Presentation AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) AU G U S T 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For the same reasons, Avient is unable to address the probable significance of the unavailable information. 3 AVIENT OVERVIEW 2023 Financial ResultsCompany Overview Revenue By: 9,300 Employees 102 Manufacturing Sites 20,000+ Customers  Innovating materials and processing solutions to solve our customers’ challenges while enabling a sustainable world  Broad portfolio of technologies with market leading positions and flexibility to anticipate and meet customer needs  Focus is on organic revenue growth and margin expansion, following our successful portfolio transformation $3.14B Revenue $2.36 Adjusted EPS $502M Adjusted EBITDA 16.0% Adjusted EBITDA Margins $186M Adjusted Free Cash Flow U.S. & Canada 64% Specialty Engineered Materials Color Additives and Inks 41% 23% 19% 10% 5% 4% Building & Energy Telecom Geography Segment Industry 2024 Financial Guidance $515 to $540 million Adjusted EBITDA $2.55 to $2.70 Adjusted EPS 4 Industry Sustainability Standards ESG Ratings Performance 1 4 87th 94th percentile Avient CDP Score: A- SUSTAINABILITY PERFORMANCE AND RECOGNITION AU G U S T 6 , 20 24 W EB CAS T P RE SE N TATI O N 6 Q2 2024 HIGHLIGHTS • 5% organic sales growth supported by broad-based growth across all regions in both CAI and SEM segments • Growth stemmed from gaining share, winning new product specifications and restocking in certain end markets • Cost control and operational discipline expanded EBITDA margins by 100 bps • EPS exceeded guidance by $0.05 and increased 21% vs the prior year Adj. EPS +21% $143 million +9% $143 million +9% Net Sales $850 million +3% (+5% ex FX) Net Sales $850 million +3% (+5% ex FX) Margin 16.9% +100 bps Margin 16.9% +100 bps Q 2 2024 R ES U LT S Q2 2024 PERFORMANCE VS.

Toxic Reduction Options for Implementation Description of the toxic reduction option(s) to be implemented Is there a statement that no option will be implemented?  * Yes, we are not implementing If you answered “No” to this question, please add the option(s) under the appropriate Toxic Substance Reduction Categories (e.g.  If you answered “Yes” please select the appropriate reason(s) in the picklist below for why no option was implemented for this substance at your facility. 

s/ ROBERT M. s/    Robert M. s/    Robert M.

The two new formulations for cable jacketing, ECCOH™ 5565 and ECCOH™ 5978 UV expand Avient’s solutions range and can improve the lifetime of cables.  ECCOH 5978 UV formulations combine high flame retardancy (up to CPR class B2ca, s1, a1, d) and good char forming properties with great ESCR. These formulations also provide excellent UV resistance protecting outdoor/indoor cables from varying weather conditions.  

Location(s) North Haven, CT As a valued customer (“Customer”) of NEU Specialty Materials, LLC (“NEU”), NEU is communicating this Quality Commitment to communicate the quality parameters, expectations and risk surrounding quality matters for the products NEU supplies. This document is property of Avient Corporation and may not be reproduced or communicated to third parties without authorization. 5.5 Regulatory Documents: A document referencing the then-current regulatory status of the applicable product(s) at the time of shipment. Upon notification from the NEU supplier, NEU will notify the Customer of the effect on the manufacture of the compound(s) (such as raw material availability, vendor name changes, vendor manufacturing location, and vendor nomenclature). 9.0 CUSTOMER FEEDBACK 9.1 NEU will use commercially reasonable efforts to (i) acknowledge receipt of Customer complaints within one business day; (ii) conduct an investigation and communicate a resolution to Customer within 30 days after receipt of the complaint.

KAYLINE RED STAN-TONE HCC-35591 RED UV ESCO ORANGE RPVC 3

XB465 PCT6730-2009 PPSU RED HC HIPS COOL GRAY 6C UV BIO RED PHA

WARM RED C PX-21415-D 019 RED PLASTISOL OPTI SMOOTH BLUE W/ UV